RIGI and neoplasm: This is the ideal location for ppp-BCL2 dsRNA delivery because it simultaneously acts as a RIG-I agonist inducing pro-CTL Th1-skewing (e.g., IFNα/β) cytokines and silences the anti-apoptotic BCL2 gene, making the tumor more vulnerable to the immune response.